Latest Cynata Therapeutics News

Cynata Therapeutics will raise approximately $912,962 after shareholders subscribed for just 25.8% of its fully underwritten entitlement offer. Caravel Securities will fund the remaining shortfall, leaving the biotech reliant on the underwriter to complete the raise.

Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.

Cynata Therapeutics has opened a fully underwritten $913,000 entitlement offer to fund adviser, director and consultant fees, offer costs and working capital. Eligible shareholders can buy three new shares for every eight held, with free options attached.

Cynata Therapeutics has lodged a replacement prospectus for a fully underwritten $913,000 entitlement offer, with the cash earmarked largely for adviser costs, intellectual property maintenance and working capital. The raising gives the biotech a near-term funding bridge, but the prospectus again flags a material uncertainty over its ability to continue as a going concern.

Cynata Therapeutics has launched a fully underwritten $913,000 entitlement offer as it reassesses the future of its Cymerus platform after two major trials failed to demonstrate efficacy. The raise provides short-term funding, but the prospectus warns that further capital may be needed and repeats a material uncertainty over going concern.

Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.

Cynata Therapeutics (ASX: CYP) has had its trading suspension lifted immediately following the publication of results from its Phase 3 Osteoarthritis and Phase 2 Graft versus Host Disease clinical trials.

Cynata Therapeutics secures a crucial regulatory green light from the EMA’s Paediatric Committee for its CYP-001 treatment in children with acute graft versus host disease, paving the way for sequential adult and paediatric trials in Europe.

Cynata Therapeutics has secured A$1.5 million through an institutional placement priced at a 22.5% discount, aiming to extend its cash runway ahead of pivotal Phase 3 and Phase 2 trial results expected in May and June 2026.

Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.

Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.